NewsRoom Articles - Page 42 of 219

MondayJun 17, 2024 10:00 am

Robotics Could Revolutionize Medical Diagnostics

Conventional healthcare employs the use of manual testing techniques that are prone to delays and errors. These errors may affect patient care and diagnosis, leading to loss of valuable time for treatment. Robots can be used in different tasks in the healthcare landscape, including analyzing samples and measuring solutions. This allows for results to be released faster and decisions on treatment to be made quicker. The use of robots also reduces errors and increases chances of accurate diagnoses. Additionally, robots prioritize patient safety and care. So, what are some of the other advantages of robots in labs? Decreased contamination risk…

FridayJun 14, 2024 10:00 am

New Study Stings Medicare Advantage, Calls for Abolition

A recently conducted analysis that examined plans under Medicare Advantage has called for the program, which costs taxpayers in America huge sums, to be abolished. The analysis highlights how, since 2007, the program has fleeced more than $600 billion from the federal government, which offers insurers a lump sum for every patient. In the last 12 months alone, Medicare Advantage plans has surcharged the federal government $82 billion. Currently, these plans are used by over one-half of the eligible population under Medicare. The plans use different strategies to charge higher payments. The paper states that despite these surcharges, Medicare Advantage…

FridayJun 14, 2024 9:45 am

Astrotech Corp. (NASDAQ: ASTC) Expands Role of Mass Spectrometry in Industrial Processes

In the chemical manufacturing industry, innovative uses of mass spectrometry are a game-changer by ensuring quality control, increased yields, and increased profits Astrotech subsidiary, Pro-Control Inc., has positioned its product line between the need for the chemical manufacturers to offset lower prices with efficiency gains that could offset potential losses The Pro-Control Maximum Value Processing(TM) can perform in-situ process tests every 5 minutes greatly increasing efficiency across a wide range of chemical manufacturing processes Mass spectrometry (“MS”) is becoming a transformative analytical technique that has revolutionized how materials are tested and processed in various industries, such as petrochemical. The supreme…

FridayJun 14, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Neurodegenerative Diseases

INM is advancing INM-089 targeting age-related macular degeneration and INM-901 targeting Alzheimer’s disease The company recently posted positive results for INM-089 demonstrating significant functional and pathological improvements in an AMD disease model Recent preclinical data for INM-901 displayed positive pharmacological effects for treating Alzheimer's disease INM posted a business update for Q3-2024 reporting a closing cash position of US$7.9 million and revenue growth for subsidiary BayMedica, a supplier of rare cannabinoids as ingredients InMed Pharmaceuticals (NASDAQ: INM), a is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s…

WednesdayJun 12, 2024 10:00 am

Researchers Say Brain ‘Overgrowth’ Could Contribute to Autism Development

Researchers have always been stumped by why some kids with autism experience symptoms such as an inability to speak, social struggles, and developmental delay, while the milder symptoms of other individuals diagnosed with autism actually improve over time. Now, new research has determined that severe autism may be associated with overgrowth in the brain’s outer layer during the gestation period. For their research, investigators obtained blood stem cells from 10 children aged between one year of age and four years of age. Their objective was to develop 3D models of each child’s cortexes using lab cell cultures. Once this was…

TuesdayJun 11, 2024 10:30 am

HealthLynked Corp. (HLYK) CEO Provides $1 Million Financing to Speed Company’s Continued Success in Revolutionizing Healthcare Industry

HealthLynked CEO Dr. Michael Dent recently provided $1 million in financing to the company, expected to accelerate its growth and expand its offerings Under Dr. Dent’s leadership, the company has developed an expansive array of products and services, including a comprehensive healthcare platform that connects patients, healthcare providers, and medical facilities in a secure, more efficient and cost-effective manner The company’s services include online medical records storage, online appointment scheduling for doctors nationwide, telemedicine, patient engagement tools, an e-commerce platform for over 15,000 name-brand medical supplies, concierge patient support, nurse chat, a reward points program, and co-management of family members’…

MondayJun 10, 2024 10:00 am

Delays in Diagnosing MS Highlight Need for More Awareness, Research

A new report has called attention to the need to increase investment in multiple sclerosis (MS) research and boost awareness of the illness. The report, which was released on World Multiple Sclerosis Day, was produced by MS Australia. Currently, more than 30,000 Australians live with multiple sclerosis. This is a chronic illness that affects the spinal cord and brain. Researchers have observed that the number of individuals being diagnosed with this condition has been growing at an alarming rate. The study found that the average time from when a patient began presenting with the disease’s symptoms to diagnosis was almost…

MondayJun 10, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’

Recent Achievements Annovis Bio recently announced statistically significant data from its Phase II/III Alzheimer’s study, showcasing Buntanetap’s potential to improve cognition in patients with mild AD Annovis Bio recently announced last patient last visit in the Phase III study of Buntanetap in patients with early Parkinson’s disease and expects data announcement in June 2024, marking significant progress in expanding its therapeutic reach The company has solidified strategic partnerships to enhance its research capabilities and broaden its market reach Investment Considerations Unique Market Position: Annovis Bio is the only company developing a drug for both AD and PD that inhibits multiple neurotoxic…

FridayJun 07, 2024 10:00 am

NIH Researchers Unveil AI Tool to Predict Oncology Patients’ Response to Immunotherapy

Scientists at the National Institutes of Health have designed an artificial intelligence (AI) tool that can predict if a patient’s cancer will respond to immune checkpoint inhibitors using clinical data. This artificial intelligence model may assist physicians in determining whether immunotherapy medications are effective in the treatment of different cancers. To determine the effectiveness of their machine-learning model, the researchers carried out a proof-of-concept study led by scientists from Memorial Sloan Kettering Cancer Center and the National Cancer Institute’s Center for Cancer Research. Their model was built and assessed using data from independent data sets, including more than 2,800 patients…

WednesdayJun 05, 2024 10:30 am

Astrotech Corp. (NASDAQ: ASTC) Subsidiary, “1st Detect”, Focuses on Superior Narcotics Trace Detection For Airport and Other Security Sites

Astrotech Corporation Subsidiary 1st Detect Approved as GSA Vendor; Introduces Advanced Narcotics Trace Detection Technology 1st Detect has now received approval from the U.S. General Services Administration (“GSA”) as an authorized vendor for government-related applications 1st Detect recently introduced a state-of-the-art Narcotics Trace Detection (“NTD”) narcotics library, which is particularly useful for detection at points of entry and government agencies involved in combating the illicit drug trade 1st Detect's portfolio now includes the TRACER 1000, Explosives Trace Detection (“ETD”) and Narcotics Trace detection Astrotech (NASDAQ: ASTC), through its subsidiary 1st Detect, is revolutionizing narcotics and explosives trace detection. With recent…